News

December 14, 2018December 14, 2018

Study Links Certain High-density Lipoproteins, Better Survival in PAH Patients

News, PAH News

Higher levels of certain high-density lipoproteins (HDLs) improve the survival of pulmonary arterial hypertension (PAH) patients, according to a recent evaluation of two PAH patient cohorts. Targeting certain HDL ... Read more

December 13, 2018December 13, 2018

Analytics 4 Life, Actelion Testing Non-invasive Diagnostic Tool CorVista for PH

News, PH News

Analytics 4 Life and Actelion Pharmaceuticals have announced a collaboration agreement to test CorVista as a potential cardiac imaging technology for the diagnosis of pulmonary hypertension (PH). CorVista is ... Read more

December 12, 2018December 12, 2018

Genetic Variants Near Two Genes Linked to PAH Risk, Large Study Reports

News, PAH News

Genetic variants close to the SOX17 and the HLA-DPB1 genes are linked to pulmonary arterial hypertension (PAH), according to the findings of the largest genetic study to date in PAH patients. The ... Read more

December 10, 2018December 10, 2018

Study Suggests DLCO as Indicator of Survival in Group 3 Pulmonary Hypertension

News, PH News

Low diffusing capacity of the lung for carbon monoxide (DLCO) is a key indicator of mortality in group 3 pulmonary hypertension (PH), according to a study. The finding suggests ... Read more

December 7, 2018December 7, 2018

Switching from Tyvaso to Uptravi Safe, Convenient for PAH Patients, Phase 3b Study Finds

News, PAH News

Switching treatment from United Therapeutics’ Tyvaso (inhaled treprostinil) to Actelion’s Uptravi (oral selexipag) is safe and considered convenient by patients with pulmonary arterial hypertension (PAH), a Phase 3b study reports. ... Read more

December 5, 2018December 6, 2018

Uptravi, PAH Treatment, Now Publicly Funded in 9 of 10 Canadian Provinces

News, PAH News

Uptravi (selexipag) is now available with public funding for pulmonary arterial hypertension (PAH) patients in Canada living in nine of the country’s 1o provinces, patient groups announced. The governments ... Read more

December 3, 2018December 4, 2018

Morphogen-IX Announces MGX292 as Treatment Candidate for PAH

News, PAH News

Biotechnology company Morphogen-IX recently announced that it will be further developing MGX292 as its treatment candidate for pulmonary arterial hypertension (PAH). The company’s decision is supported by previous preclinical studies ... Read more

November 30, 2018December 4, 2018

PhaseBio Advances New Phase 2b Trial to Test PB1046 in Patients with PAH

News, PAH News

PhaseBio Pharmaceuticals started dosing its investigational compound PB1046 in patients with pulmonary arterial hypertension (PAH) in a Phase 2b clinical trial. The first patient to receive the therapy was ... Read more

November 29, 2018December 5, 2018

Specific Bone Marrow Cells Drive PAH Development, Blocking Serotonin Receptors a Potential Treatment, Study Suggests

News, PAH News, PH News

A subset of bone marrow cells known as proangiogenic cells (PACs) may drive the development of pulmonary arterial hypertension (PAH), according to a study that also showed that blocking ... Read more

November 28, 2018November 29, 2018

First Clinical Site Announced for Phase 2 Trial Testing Levosimendan for PH Linked to Heart Disease

News, PH News

The Stanford University School of Medicine is the first clinical site for a Phase 2 trial testing levosimendan as a potential treatment for pulmonary hypertension associated with heart failure and ... Read more

Pin It on Pinterest